Trending...
- San Antonio Board of REALTORS® Among First to Use Passkey Login with Solid Earth's SSO Dashboard - 158
- Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
Download
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
(Photo: Business Wire)
NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health (HCCIH-a division of the NIH) is providing funding for this trial which will be conducted at the NYU Grossman School of Medicine. (Clinical Trials.gov Identifier: NCT05571592)
More on Colorado Desk
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Colorado: Gov. Polis Urges House to End the Madness and Do Right by Coloradans by Starting Over on Federal Bill
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
The Principal Investigators for the trial are Naomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine and Esther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial will study Nantheia™ A1002N5S versus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker.
"We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition," said Dr Simon.
Dr. Blessing noted, "It is exciting to be moving forward with clinical trials that build upon promising preclinical results for CBD as a treatment for anxiety disorders."
"We are very pleased to again be working with Dr Simon and Dr Blessing on this important trial that could impact the lives of a large number of people," said Sohail R. Zaidi, ANANDA's CEO. "We look forward to further advancing applications for our investigational drug Nantheia A1002N5S in an indication with a significant unmet medical need."
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20220308005059%2Fen%2FANANDA-Scientific-and-NYU-Grossman-School-of-Medicine-Announce-First-Patient-Enrolled-in-the-Clinical-Trial-for-Opioid-Sparing-in-Participants-with-Radiculopathic-Pain&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Radiculopathic+Pain&index=8&md5=1583bdfab3e5aa6e72280a53ccffcde5), Anxiety and Opioid Use Disorder (Mt. Sinai (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20211019005004%2Fen%2FANANDA-Scientific%25E2%2580%2599s-Liquid-Structure%25E2%2584%25A2-Cannabidiol-CBD-to-Be-Clinically-Evaluated-for-Opioid-Use-Disorder&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Mt.+Sinai&index=9&md5=c7390692cddb3baae153188a12f6d0d6) and UCLA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fananda-scientific-announces-first-patient-enrolled-in-the-clinical-trial-on-the-treatment-of-opioid-use-disorder-oud-301592512.html%3F%3Dprn&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=UCLA&index=10&md5=4423441644a84137a53b0c9ef1100ba5)). The company employs patented delivery technology, (licensed from Lyotropic Delivery Systems (LDS) Ltd (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.lds-biotech.com%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Lyotropic+Delivery+Systems+%28LDS%29+Ltd&index=11&md5=68fda5da92aba5885ea6a7e3c59451c7), in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium pharmaceutical products.
More on Colorado Desk
- New Housing and Public Safety Laws Take Effect to Save Coloradans Money on Housing and Make Colorado Safer
- Morris Animal Foundation Names Ike Nicoll as Chief Executive Officer
- 20/20 Institute Announces Expansion with New State-of-the-Art LASIK Center in Colorado Springs
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Ananda Scientific (https://www.linkedin.com/company/ananda-scientific)
Contacts
ANANDA Scientific Media Relations | Christopher Moore (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchrismoore1%2F&esheet=52981086&newsitemid=20221129005218&lan=en-US&anchor=Christopher+Moore&index=12&md5=86a83b4951580a0d495debb7aa609c7c) | 813 326 4265 | media@anandascientific.com
Filed Under: Business
0 Comments
Latest on Colorado Desk
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- Colorado: Governor Polis Appoints Rory N. Devlin to the Elbert County Court in the 23rd Judicial District
- Governor Polis, Office of Economic Development and International Trade Celebrate Sale of EVRAZ North America including Rocky Mountain Steel in Pueblo, Welcomes Atlas Holdings to Colorado
- Colorado: Delivering Passenger Rail: Governor Polis Celebrates Major Step Towards Delivering Northern Front Range Passenger Rail
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- Colorado Springs: Mayor certifies 2025 Special Election results
- Technologist Jay Harris Delivers Keynote for DenverDevDay
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)
- Jones Law Firm, PC Refreshes Denver Child Support Services Page to Better Serve Colorado Families
- Colorado: Governor Polis: U.S. Supreme Court Makes it More Difficult to Protect Constitutional Rights, Creates Chaos
- Colorado: Governor Polis, Hospital Leaders, Health Care Advocates: Devastating Cuts Should Be Removed From Federal Budget Bill
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
- Stonebridge and Stout NYC Hospitality Group Introduce New Era for The MC Hotel, Autograph Collection in Montclair, NJ
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research